China Pharma Holdings (CPHI) Notes Payables (2010 - 2026)

China Pharma Holdings (CPHI) has reported Notes Payables for 16 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Notes Payables rose 16.85% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (up 16.85% YoY), and the FY2025 full-year result was $1.4 million, up 25.34% from the prior year.
• Notes Payables advanced to $1.6 million in Q2 2026 per CPHI's latest filing, from $1.5 million in the prior quarter.
• Across five years, Notes Payables topped out at $4.6 million in Q3 2022 and bottomed at $315428.0 in Q3 2024.
• Historically, Notes Payables has averaged $1.7 million across 5 years, with a median of $1.4 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Notes Payables sank 84.44% in 2024, then soared 348.07% in 2025.
• Over 5 years, Notes Payables stood at $3.8 million in 2022, then sank by 70.16% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024, then gained by 25.34% to $1.4 million in 2025, then increased by 14.61% to $1.6 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $1.6 million, $1.5 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.